Skip to content

Multimodal Quantified Analysis of Facial Movements: Comparison Between Pathological and Control Subjects

Multimodal Quantified Analysis of Facial Movements: Comparison Between Pathological

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05581680
Acronym
AQ2MF
Enrollment
720
Registered
2022-10-14
Start date
2022-10-12
Completion date
2028-10-31
Last updated
2025-05-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Electromyography, Eye-tracking, Facial Palsy

Keywords

facial mimics, motion capture, electromyography, eye-tracking, Facial Palsy

Brief summary

The facial palsy is a frequent disease with a lot of etiologies. It has variable severities with sometimes heavy functional repercussions and different recovery potentials. The proposed treatments are based on surgery, physiotherapy and botulinum toxin injections. However, when recovery is incomplete, acceptance is more difficult, with an impacted quality of life. Thanks to Motion Capture and Electromyography, a quantification of the facial mimicry is now possible with a great precision. In addition with the quantification of the facial mimicry, eye-tracking, wich is widely used in the marketing field, but it also finds medical applications including head and neck lesions and facial palsy in particular, will be used to evaluate the visio of the patients on their pathology in function of the movement quantification measured with MoCap and Electromyography. The aim of this research is to measure in a combined way the action potentials by sEMG and the amplitudes of displacement of the markers in motion capture, for movements determined in a population of patients presenting a facial pathology, in order to compare them with reference values obtained in healthy subjects. In a second step, the aim will be to study if there is a link between the way the patient looks at his pathology and the results of his management (treatment, rehabilitation) which will be quantitatively evaluated thanks to MoCap and sEMG.

Interventions

dental impressions

OTHERSimultaneous MoCap and EMG acquisition

Simultaneous MoCap and EMG acquisition

OTHEREye-tracking acquisition for pathological subjects

Eye-tracking acquisition for pathological subjects

OTHERFollow-up visit for pathological subjects

Follow-up visit for pathological subjects

Sponsors

Centre Hospitalier Universitaire, Amiens
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Subjects with no known facial pathology (healthy volunteers) OR * Patients with peripheral facial palsy, irrespective of grade, whether or not previously treated * Subject with written informed consent * Subject over 18 years of age * Subject affiliated to a social security scheme

Exclusion criteria

* Subjects with severe skin disorders that do not allow the application of electrodes or photo reflective markers * Subjects with speech disorders making it impossible to pronounce the sounds \[o\] and \[pu\] * Subject unable to provide written informed consent * Subjects under guardianship, curators or safeguard of justice

Design outcomes

Primary

MeasureTime frameDescription
determination of baseline values of facial mimicry (in millimetres) in healthy volunteersone monthdetermination of baseline values of facial mimicry (in millimetres) in healthy volunteers
determination of baseline values of eye-tracking (in millimetres) in healthy volunteersone monthdetermination of baseline values of eye-tracking (in millimetres) in healthy volunteers
determination of the maximum range of motion of facial mimicry (in millimetres) in patientsone yeardetermination of the maximum range of motion facial mimicry (in millimetres) in patients
determination of the maximum range of motion of eye-tracking (in millimetres) in patientsone yeardetermination of the maximum range of motion of eye-tracking (in millimetres) in patients

Countries

France

Contacts

Primary ContactStéphanie Dakpé, Pr
dakpe.stephanie@chu-amiens.fr03 22 08 90 50

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026